Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN

Bone Marrow Transplantation volume 46, pages 835–839 (2011)Cite this article

Subjects

Abstract

Although autologous tandem hematopoietic SCT has improved the prognosis of patients with advanced high-risk neuroblastoma, the results remain unsatisfactory. In an attempt to induce the graft-versus-tumor effect, we performed autologous PBSCT followed by allogeneic cord blood transplantation in three consecutive advanced neuroblastoma cases with marked BM infiltration and high MYCN amplification. Severe acute complications did not occur in any patient and they have maintained disease-free survival for 37–60 months. This strategy appears to be feasible and effective for the treatment of extremely high-risk neuroblastoma cases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165–1173.

    Article  CAS  Google Scholar 

  2. Frappaz D, Michon J, Coze C, Berger C, Plouvier E, Lasset C et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000; 18: 468–476.

    Article  CAS  Google Scholar 

  3. Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 2002; 24: 613–621.

    Article  Google Scholar 

  4. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592–1601.

    Article  CAS  Google Scholar 

  5. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: 649–658.

    Article  CAS  Google Scholar 

  6. Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008; 51: 747–753.

    Article  Google Scholar 

  7. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002; 20: 2284–2292.

    Article  CAS  Google Scholar 

  8. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006; 24: 2891–2896.

    Article  Google Scholar 

  9. Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant 2007; 40: 37–45.

    Article  CAS  Google Scholar 

  10. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O’Leary MC, Harris RE et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol 1994; 12: 2382–2389.

    Article  CAS  Google Scholar 

  11. Ladenstein R, Lasset C, Hartmann O, Klingebiel T, Bouffet E, Gadner H et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 37–46.

    CAS  PubMed  Google Scholar 

  12. Inoue M, Nakano T, Yoneda A, Nishikawa M, Nakayama M, Yumura-Yagi K et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 2003; 32: 103–106.

    Article  CAS  Google Scholar 

  13. Hirayama M, Azuma E, Araki M, Komada Y, Nakagawa A . Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma. Transplantation 2006; 82: 142–144.

    Article  Google Scholar 

  14. Marabelle A, Paillard C, Tchirkov A, Halle P, Chassagne J, Demeocq F et al. Graft-versus-tumour effect in refractory metastatic neuroblastoma. Bone Marrow Transplant 2007; 39: 809–810.

    Article  CAS  Google Scholar 

  15. Williams KM, Gress RE . Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2008; 21: 579–596.

    Article  CAS  Google Scholar 

  16. Beziat V, Nguyen S, Lapusan S, Hervier B, Dhedin N, Bories D et al. Fully functional NK cells after unrelated cord blood transplantation. Leukemia 2009; 23: 721–728.

    Article  CAS  Google Scholar 

  17. Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB . Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 1985; 135: 242–246.

    CAS  PubMed  Google Scholar 

  18. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY . Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994; 83: 1323–1328.

    CAS  PubMed  Google Scholar 

  19. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23: 492–500.

    Article  CAS  Google Scholar 

  20. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006; 17: 1134–1140.

    Article  CAS  Google Scholar 

  21. Jubert C, Wall DA, Grimley M, Champagne MA, Duval M . Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial. Bone Marrow Transplant (e-pub ahead of print 3 May 2010; doi:10.1038/bmt.2010.107).

  22. Hobbie WL, Moshang T, Carlson CA, Goldmuntz E, Sacks N, Goldfarb SB et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 2008; 51: 679–683.

    Article  Google Scholar 

  23. Yamashiro DJ, Lee A, Bhatia M, Glade-Bender J, Qualter E, Militano O et al. Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma: a single institution pilot study. Biol Blood Marrow Transplant 2007; 13: 68–69.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

    K Goi, T Inukai, H Honna, K Akahane, K Hirose, I Kuroda & K Sugita

  2. Second Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

    N Hasuda, K Koshizuka & K Takano

Authors
  1. K Goi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Inukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Honna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Akahane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Kuroda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Hasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Koshizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Sugita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Goi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goi, K., Inukai, T., Honna, H. et al. Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN. Bone Marrow Transplant 46, 835–839 (2011). https://doi.org/10.1038/bmt.2010.191

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.191

Keywords

This article is cited by

Search

Advanced search

Quick links